BioNTech Enters Into Settlements With NIH, UPenn Over COVID …
5 days ago · BioNTech Enters Into Settlements With NIH, UPenn Over COVID-19 Vaccine Royalties December 30, 2024 Reuters (12/27, Satija, S K) reported, “BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its COVID-19 vaccine ...
BioNTech settles with U.S. agency, University of Pennsylvania over ...
Dec 27, 2024 · BioNTech reached settlements with the U.S. National Institutes of Health and the University of Pennyslvania over royalties related to its Covid-19 vaccine.
BioNTech to Pay Up to $1.26B in Covid-19 Vaccine ... - MarketWatch
Dec 27, 2024 · BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine.
BioNTech enters settlement with US agency, UPenn over COVID …
Dec 27, 2024 · BioNTech said partner Pfizer will reimburse it for up to $170 million of the royalties payable to Penn and $364.5 million of the royalties paid to the National Institutes of Health (NIH)for 2020 ...
Penn to receive $467M from BioNTech in COVID-19 vaccine …
3 days ago · BioNTech also disclosed last week a settlement with the National Institutes of Health for $791.5 million, including $750 million in royalties for patents held by the U.S. government. Pfizer will reimburse BioNTech for $364.5 million for its share. As in the Penn settlement, BioNTech noted that the agreement is not an admission of liability.
BioNTech Enters Into Settlements With U.S. Agency ... - Markets …
Dec 27, 2024 · (RTTNews) - BioNTech SE (BNTX), Friday reached two separate settlements with the U.S. National Institutes of Health, and the University of Pennsylvania regarding the royalties payment of COVID-19 ...
BioNTech Settles Royalty Dispute with NIH for $791.5 Million
Dec 27, 2024 · BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine ...
COVID: BioNTech to pay $1.2 billion over vaccine royalties
Dec 28, 2024 · COVID: BioNTech to pay $1.2 billion over vaccine royalties 12/28/2024 December 28, 2024. German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to ...
Newsroom - BioNTech
Videos, photos, press releases or data sheets Learn more about BioNTech!
BioNTech Announces Positive Topline Phase 2 Results for mRNA ...
Jul 30, 2024 · The randomized trial evaluates the clinical activity and safety of the investigational mRNA cancer immunotherapy BNT111 in combination with Libtayo ® (cemiplimab), an anti-PD-1 monoclonal antibody being developed by Regeneron, and assesses the two single agents alone.